Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

NCT06095583 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

756

Enrollment

OTHER

Sponsor class

Conditions

Limited-stage Small Cell Lung Cancer (LS-SCLC)

Interventions

DRUG: Tifcemalimab injection
DRUG: toripalimab injection
DRUG: Placebo for Tifcemalimab
DRUG: Placebo for toripalimab

Sponsor

Shanghai Junshi Bioscience Co., Ltd.